Clinical Report: Effects of β-glucan Yeast Extract on Melanoma Progression

Overview

This study evaluates the effects of β-glucan yeast extract (β-GESc) on melanoma progression in a murine model, demonstrating its potential to enhance immune response and reduce tumor growth. Key findings include increased splenocyte counts and improved survival rates in treated mice.

Background

Melanoma is a highly aggressive skin cancer with poor prognosis in advanced stages. Current therapies often face challenges due to the tumor's ability to evade the immune response. Understanding novel immunomodulatory strategies, such as β-glucan from Saccharomyces cerevisiae, is crucial for improving treatment outcomes.

Data Highlights

Key Findings

• β-GESc treatment increased spleen size and splenocyte counts.
• Enhanced expression of MHC class II on dendritic cells was observed.
• Improved survival rates were noted in treated mice compared to controls.
• Increased counts of CD4+ and CD8+ T cells producing IFN-γ and TNF-α were recorded.
• Treated mice showed preserved spleen architecture with reduced tumor infiltration.

Clinical Implications

The findings suggest that β-GESc may serve as an effective immunomodulatory agent in melanoma treatment, potentially enhancing the efficacy of existing therapies. Clinicians may consider exploring β-glucan as an adjunct therapy to improve patient outcomes.

Conclusion

β-GESc demonstrates significant immunomodulatory effects that could contribute to better control of melanoma progression. Further studies are warranted to evaluate its clinical applicability in human subjects.

References

1. The ASCO Post, Active Hexose Correlated Compound Guest Editor OF NOTE, 2020 -- Active Hexose Correlated Compound
2. The ASCO Post, New Data Reported on Melanoma, Cutaneous T-cell Lymphoma, Basal Cell Carcinoma, and Cancer Treatment Side Effects, 2013 -- New Data Reported on Melanoma
3. The ASCO Post, Intralesional Injections Trigger Immune Responses in Melanoma Related Articles, 2014 -- Intralesional Injections Trigger Immune Responses in Melanoma
4. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, PubMed, 2024 -- Cutaneous melanoma: ESMO Clinical Practice Guideline
5. Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial, PubMed, 2024 -- Adjuvant Pembrolizumab
6. The ASCO Post — Intralesional Injections Trigger Immune Responses in Melanoma Related Articles
7. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
8. Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial - PubMed